SNSESensei Biotherapeutics, Inc.

Nasdaq senseibio.com


$ 0.67 $ 0.02 (3.03 %)    

Monday, 10-Jun-2024 11:29:57 EDT
QQQ $ 463.33 $ 0.54 (0.12 %)
DIA $ 389.03 $ 0.68 (0.18 %)
SPY $ 534.57 $ 1.32 (0.25 %)
TLT $ 90.83 $ -0.20 (-0.22 %)
GLD $ 213.77 $ 0.68 (0.32 %)
$ 0.6503
$ 0.67
$ 0.00 x 0
$ 0.00 x 0
$ 0.67 - $ 0.67
$ 0.51 - $ 1.94
108,265
na
16.29M
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-29-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-15-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citigroup-reinstates-buy-on-sensei-biotherapeutics-announces-4-price-target

Citigroup analyst Samantha Semenkow reinstates Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy and announces $4 price target.

 hc-wainwright--co-reiterates-buy-on-sensei-biotherapeutics-maintains-4-price-target

HC Wainwright & Co. analyst Edward White reiterates Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy and maintains $4 pri...

 stephens--co-reiterates-overweight-on-sensei-biotherapeutics-maintains-5-price-target

Stephens & Co. analyst Sudan Loganathan reiterates Sensei Biotherapeutics (NASDAQ:SNSE) with a Overweight and maintains ...

 stephens--co-initiates-coverage-on-sensei-biotherapeutics-with-overweight-rating-announces-price-target-of-5

Stephens & Co. analyst Sudan Loganathan initiates coverage on Sensei Biotherapeutics (NASDAQ:SNSE) with a Overweight rat...

 sensei-biotherapeutics-to-present-topline-clinical-data-from-the-sns-101-phase-i-dose-escalation-study-at-the-2024-asco-annual-meeting

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development o...

 sensei-biotherapeutics-announces-nature-communications-publication-describing-mechanism-of-action-of-sns-101-selectively-targeting-the-active-form-of-vista-within-the-tumor-microenvironment

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development o...

 sensei-biotherapeutics-cfo-to-resign-all-positions-with-co-effective-april-10

-SEC Filing

 sensei-biotherapeutics-fy-eps-122-up-from-158-yoy-2023-year-end-cash-cash-equivalents-and-marketable-securities-of-658m-is-expected-to-provide-cash-runway-into-fourth-quarter-of-2025

Sensei Biotherapeutics (NASDAQ:SNSE) reported quarterly losses of $(1.22) per share. This is a 22.78 percent increase over loss...